Related Experiment Videos
Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins
1Cancer Center, University of Illinois at Chicago, 60607-7173, USA.
Abstract:
The problem of tumor cell drug resistance remains a barrier to the successful treatment of many neoplastic diseases. Problems of tumor cell heterogeneity and expression of multiple mechanisms of drug resistance complicate treatment strategies. Indeed, even that form of resistance to natural product anticancer agents, multidrug resistance (MDR), can have multiple mechanisms. Compounding these problems is the use of different methodologies and different reagents to assess expression of the most widely studied form of MDR, that due to increased expression of the MDR1 gene and its product, P-glycoprotein (Pgp). In this paper, we discuss problems associated with assay variability and accurate measurement of markers of drug resistance, and summarize consensus findings of the St Jude Workshop on methods to detect Pgp in tumors.
Insights
Tumor cell drug resistance, including multidrug resistance (MDR), hinders cancer treatment. This study addresses challenges in accurately measuring drug resistance markers like P-glycoprotein (Pgp) to improve therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor cell drug resistance is a significant obstacle in treating neoplastic diseases.
- Tumor heterogeneity and multiple drug resistance mechanisms complicate treatment.
- Multidrug resistance (MDR), particularly P-glycoprotein (Pgp) mediated, has diverse underlying mechanisms.
Purpose of the Study:
- To discuss challenges in assay variability and accurate measurement of drug resistance markers.
- To summarize consensus findings from the St Jude Workshop on detecting Pgp in tumors.
- To address the need for standardized methodologies in assessing drug resistance.
Main Methods:
- Review of methodologies for assessing drug resistance markers.
- Discussion of reagent variability in Pgp detection.
- Summarization of expert consensus on Pgp detection methods.
Main Results:
- Significant variability exists in current methods for assessing drug resistance.
- Inconsistent methodologies and reagents complicate accurate Pgp measurement.
- Consensus was reached on key aspects of Pgp detection in tumor samples.
Conclusions:
- Standardization of methods is crucial for accurate assessment of drug resistance markers.
- Improved detection of Pgp can lead to more effective cancer treatment strategies.
- Addressing assay variability is essential for overcoming drug resistance barriers.